Search
Search Results
##search.searchResults.foundPlural##
-
Diagnosis of del(5q) MDS, 14 years after JAK-2 positive PV appearance: complete remission of both diseases with lenalidomide monotherapy
2957PDF: 819HTML: 1328Blood Count trend before and during lenalidomide treatment: 239Light micrograph of bone marrow biopsy of a patient with PV and 5q deletion: 239 -
BACK TO THE “GOLD STANDARD”: HOW PRECISE IS HEMATOCRIT DETECTION TODAY? Novel ImageJ-based approach for the precise hematocrit measurement
2674PDF: 958HTML: 1236 -
Should every patient with MDS get iron chelation – probably yes.
2429PDF: 1015HTML: 403 -
IMPLEMENTATION OF MICROELIMINATION STRATEGY IN ERADICATION OF CHRONIC HEPATITIS C INFECTION IN PATIENTS WITH HEMOPHILIA IN THE NORTHERN REGION OF SERBIA Microelimination Strategy of Chronic Hepatitis C Infection in patients with Hemophilia
1000PDF: 463HTML: 163 -
Allogeneic transplantation in patients with advanced systemic mastocytosis: case report of a single center experience Allogeneic Transplantation in Systemic Mastocytosis
2152PDF: 169HTML: 46 -
GLUCOSE METABOLISM AND INSULIN RESPONSE TO ORAL GLUCOSE TOLERANCE TEST (OGTT) IN PREPUBERTAL PATIENTS WITH TRANSFUSION DEPENDENT Β-THALASSEMIA (TDT): A LONG-TERM RETROSPECTIVE ANALYSIS Long-term retrospective analysis of glucose homeostasis in children with transfusion dependent β-thalassemia
1978PDF: 619HTML: 261 -
A MULTICENTER ICET-A SURVEY ON ADHERENCE TO ANNUAL ORAL GLUCOSE TOLERANCE TEST (OGTT) SCREENING IN TRANSFUSION-DEPENDENT THALASSEMIA (TDT) PATIENTS - THE EXPERT CLINICIANS’ OPINION ON FACTORS INFLUENCING THE ADHERENCE AND ON ALTERNATIVE STRATEGIES FOR ADHERENCE OPTIMIZATION Survey on adherence to annual OGTT in thalassemia
3031PDF: 1416HTML: 180 -
COMPREHENSIVE REVIEW OF GENETIC AND EPIGENETICS REGULATION OF FETAL HEMOGLOBIN IN β-HEMOGLOBINOPATHIES: FROM MOLECULAR MECHANISMS TO CLINICAL APPLICATIONS HbF Genetics in Anemia
1000PDF: 707HTML: 145 -
Safety warning for ChAdOx1 nCov-19 vaccine in patients with sickle cell disease Astra Zeneca vaccine in Sickle cell disease (SCD)
2313PDF: 575HTML: 189 -
How I treat acute and persistent sickle cell pain
2137PDF: 1195HTML: 801 -
THERAPEUTIC VALUE OF COMBINED THERAPY WITH DEFERASIROX AND SILYMARIN ON IRON OVERLOAD IN CHILDREN WITH BETA THALASSEMIA
2872PDF: 898HTML: 15034Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia: 378 -
Spontaneous rupture of malarial spleen: report of two cases
890PDF: 446HTML: 2893jdoe, cover letter.doc: 216 -
THE ROLE OF THE CAROTID DOPPLER EXAMINATION IN THE EVALUATION OF ATHEROSCLEROTIC CHANGES IN BETA THALASSEMIA PATIENTS
2317PDF: 1053HTML: 3074Untitled: 277 -
FLT3 Mutated Acute Myeloid Leukemia after CD19 CAR-T Cells
1108PDF: 1306HTML: 140 -
Common variable immunodeficiency due to a novel NFKB1 variant in a child with thalassemia major CVID with thalassemia major
840PDF: 636HTML: 205 -
Sickle cell disease and Bartonella spp. infection
1417PDF: 1454HTML: 514 -
APLASTIC ANEMIA AND VIRAL HEPATITIS
1351PDF: 578HTML: 23242 -
PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC Recommendation for ITP management during COVID
2983PDF: 1023HTML: 657 -
BONE MARROW ABONRMALITIES IN HIV INFECTION
2022PDF: 1210HTML: 1787 -
OUTCOME OF ANTIFUNGAL COMBINATION THERAPY FOR INVASIVE MOLD INFECTIONS IN HEMATOLOGICAL PATIENTS IS INDEPENDENT OF THE CHOSEN COMBINATION
1307PDF: 587HTML: 1718Figures: 213Fifures Sanz: 224tables Sanz: 227Untitled: 224 -
POST-LOAD PLASMA GLUCOSE INCREASE (PG-GAP) AS A RISK FACTOR FOR DEVELOPING DYSGLYCEMIA IN PATIENTS WITH TRANSFUSION-DEPENDENT Β-THALASSEMIA (Β-TDT): RETROSPECTIVE ANALYSIS OVER 8 YEARS Post load plasma glucose increase and the risk of glucose dysregulation in thalassemia
639PDF: 298HTML: 179 -
SUSTAINED REMISSION IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA FOLLOWING GILTERITINIB TREATMENT AS THIRD-LINE SALVAGE THERAPY Long-lasting disease remission with third line therapy with gilteritinib
1076PDF: 575HTML: 344







